Dataset Information

KIF3B protein expression loss correlates with metastatic ability of prostate cancer.

ABSTRACT: Kinesin family member 3B (KIF3B) is a microtubule motor kinesin involved in mitotic progression and vasculotropism. A novel therapeutic target, it is overexpressed in several cancers [PMID 29904055]. Its significance in prostate cancer (PC) was uncertain.

Methods

89 cases, including tissue microarrays from 70 prostatectomies comprising matched cancer and benign spots, 19 additional prostatectomy tissues, plus 16 prostate cancer metastases (7 nodal and 9 distant sites; 8 had matched primary PC) were stained with rabbit polyclonal KIF3B antibody. Cytoplasmic immunoreactivity was scored: 0 (negative) to 3+ (strong and diffuse). 39 patients had no nodal metastases, 31 had positive lymph nodes, and 19 had nodes not sampled. Gleason grade groups were 1 (9), 2 (28), 3 (39), 4 (1), and 5 (12). 15 cases had cribriform pattern. AJCC stages were 2 (48), 3 (29), unknown (12).

Results

KIF3B in PC (mean 1.0) was higher than in benign prostate (mean 0.1, P<0.01, Student t-test). All 7 available nodal metastases of PC were negative. One-third of primary PCs with nodal metastases lost all expression, compared to retained expression in all but one PC without nodal metastasis (P<0.01, chi-square). The former group also had stronger staining (mean 1.0) than metastases (mean 0.3) (P<0.01, Student t-test) and had fewer cases with any positive (>0) expression compared to cases without metastases or with unsampled lymph nodes (P<0.01, chi-square test). Reactivity of paired metastatic tissue and primary PC correlated strongly (Pearson coefficient: +0.7). No significant trends were found by grade group, cribriform status, or stage.

Conclusions

KIF3B is a PC marker. Metastatic cancers showed less KIF3B expression than their primary PC counterparts, and primary cases with positive nodes demonstrated reduced positivity, suggesting use as a prognostic marker. It is possible that KIF3B protein becomes altered prior to metastases, preventing immunohistochemical detection.

SUBMITTER: Kravtsov O

PROVIDER: S-EPMC6627541 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

KIF3B protein expression loss correlates with metastatic ability of prostate cancer.

Kravtsov Oleksandr O Hartley Christopher P CP Compérat Eva-Maria EM Iczkowski Kenneth A KA

American journal of clinical and experimental urology 20190615 3

Kinesin family member 3B (KIF3B) is a microtubule motor kinesin involved in mitotic progression and vasculotropism. A novel therapeutic target, it is overexpressed in several cancers [PMID 29904055]. Its significance in prostate cancer (PC) was uncertain.<h4>Methods</h4>89 cases, including tissue microarrays from 70 prostatectomies comprising matched cancer and benign spots, 19 additional prostatectomy tissues, plus 16 prostate cancer metastases (7 nodal and 9 distant sites; 8 had matched primar ...[more]

PMID: 31317057

Similar Datasets

Project description:Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To fully capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the target proteins in tumor tissues is required. In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonstrated clinical activity. However, PSMA expression is lost in a significant number of CRPC tumors, and the identification of additional cell surface targets is necessary in order to develop new therapeutic approaches. Here, we performed a comprehensive analysis of the expression and co-expression patterns of trophoblast cell-surface antigen 2 (TROP2), delta-like ligand 3 (DLL3), and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) in CRPC samples from a rapid autopsy cohort. We show that DLL3 and CEACAM5 exhibit the highest expression in neuroendocrine prostate cancer (NEPC), while TROP2 is expressed across different CRPC molecular subtypes, except for NEPC. We observed variable intra-tumoral and inter-tumoral heterogeneity and no dominant metastatic site predilections for TROP2, DLL3, and CEACAM5. We further show that AR amplifications were associated with higher expression of PSMA and TROP2 but lower DLL3 and CEACAM5 levels. Conversely, PSMA and TROP2 expression was lower in RB1-altered tumors. In addition to genomic alterations, we demonstrate a tight correlation between epigenetic states, particularly histone H3 lysine 27 methylation (H3K27me3) at the transcriptional start site and gene body of TACSTD2 (encoding TROP2), DLL3, and CEACAM5, and their respective protein expression in CRPC patient-derived xenografts. Collectively, these findings provide novel insights into the patterns and determinants of expression of TROP2, DLL3, and CEACAM5 with important implications for the clinical development of cell surface targeting agents in CRPC.

Project description:BackgroundHomeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation.ObjectiveTo assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy.Design, setting, and participantsGenome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239).Outcome measurements and statistical analysisMultivariable Cox regressions were used to analyze metastasis-free survival (MFS).Results and limitationsHOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables.ConclusionsPrimary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression.Patient summaryUsing genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.

Project description:BackgroundMost prostate cancers express androgen receptor (AR), and our previous studies have focused on identifying transcription factors that modify AR function. We have shown that nuclear factor I/B (NFIB) regulates AR activity in androgen-dependent prostate cancer cells in vitro. However, the status of NFIB in prostate cancer was unknown.MethodsWe immunostained a tissue microarray including normal, hyperplastic, prostatic intraepithelial neoplasia, primary prostatic adenocarcinoma, and castration-resistant prostate cancer tissue samples for NFIB, AR, and synaptophysin, a marker of neuroendocrine differentiation. We interrogated publically available data sets in cBioPortal to correlate NFIB expression and AR and neuroendocrine prostate cancer (NEPCa) activity scores. We analyzed prostate cancer cell lines for NFIB expression via Western blot analysis and used nuclear and cytoplasmic fractionation to assess where NFIB is localized. We performed co-immunoprecipitation studies to determine if NFIB and AR interact.ResultsNFIB increased in the nucleus and cytoplasm of prostate cancer samples versus matched normal controls, independent of Gleason score. Similarly, cytoplasmic AR and synaptophysin increased in primary prostate cancer. We observed strong NFIB staining in primary small cell prostate cancer. The ratio of cytoplasmic-to-nuclear NFIB staining was predictive of earlier biochemical recurrence in prostate cancer, once adjusted for tumor margin status. Cytoplasmic AR was an independent predictor of biochemical recurrence. There was no statistically significant difference between NFIB and synaptophysin expression in primary and castration-resistant prostate cancer, but cytoplasmic AR expression was increased in castration-resistant samples. In primary prostate cancer, nuclear NFIB expression correlated with cytoplasmic NFIB and nuclear AR, while cytoplasmic NFIB correlated with synaptophysin, and nuclear and cytoplasmic AR. In castration-resistant prostate cancer samples, NFIB expression correlated positively with an AR activity score, and negatively with the NEPCa score. In prostate cancer cell lines, NFIB exists in several isoforms. We observed NFIB predominantly in the nuclear fraction of prostate cancer cells with increased cytoplasmic expression seen in castration-resistant cell lines. We observed an interaction between AR and NFIB through co-immunoprecipitation experiments.ConclusionWe have described the expression pattern of NFIB in primary and castration-resistant prostate cancer and its positive correlation with AR. We have also demonstrated AR interacts with NFIB.

Project description:BackgroundClinical grading systems using clinical features alongside nomograms lack precision in guiding treatment decisions in prostate cancer (PCa). There is a critical need for identification of biomarkers that can more accurately stratify patients with primary PCa.ObjectiveTo identify a robust prognostic signature to better distinguish indolent from aggressive prostate cancer (PCa).Design, setting, and participantsTo develop the signature, whole-genome and whole-transcriptome sequencing was conducted on five PCa patient-derived xenograft (PDX) models collected from independent foci of a single primary tumor and exhibiting variable metastatic phenotypes. Multiple independent clinical cohorts including an intermediate-risk cohort were used to validate the biomarkers.Outcome measurements and statistical analysisThe outcome measurement defining aggressive PCa was metastasis following radical prostatectomy. A generalized linear model with lasso regularization was used to build a 93-gene stroma-derived metastasis signature (SDMS). The SDMS association with metastasis was assessed using a Wilcoxon rank-sum test. Performance was evaluated using the area under the curve (AUC) for the receiver operating characteristic, and Kaplan-Meier curves. Univariable and multivariable regression models were used to compare the SDMS alongside clinicopathological variables and reported signatures. AUC was assessed to determine if SDMS is additive or synergistic to previously reported signatures.Results and limitationsA close association between stromal gene expression and metastatic phenotype was observed. Accordingly, the SDMS was modeled and validated in multiple independent clinical cohorts. Patients with higher SDMS scores were found to have worse prognosis. Furthermore, SDMS was an independent prognostic factor, can stratify risk in intermediate-risk PCa, and can improve the performance of other previously reported signatures.ConclusionsProfiling of stromal gene expression led to development of an SDMS that was validated as independently prognostic for the metastatic potential of prostate tumors.Patient summaryOur stroma-derived metastasis signature can predict the metastatic potential of early stage disease and will strengthen decisions regarding selection of active surveillance versus surgery and/or radiation therapy for prostate cancer patients. Furthermore, profiling of stroma cells should be more consistent than profiling of diverse cellular populations of heterogeneous tumors.

Dataset Information

KIF3B protein expression loss correlates with metastatic ability of prostate cancer.

Methods

Results

Conclusions

Publications

KIF3B protein expression loss correlates with metastatic ability of prostate cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets